ArticlemAbs

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL.

Carlos Cuesta-Mateos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.